Study to Compare the Efficacy & Safety of Ursoplus Capsules vs. UDCA vs. Placebo Among Chronic Liver Disease Patients
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This study aims to compare the efficacy & safety of Ursoplus® capsules (UDCA 250mg &
Silymarin 140mg) versus UDCA alone versus Placebo among Compensated Chronic Liver Diseased
Patients